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Background: Inhaled corticosteroids (ICS) are recommended as first-line treatment for adults
and children with persistent asthma. The Global Initiative for Asthma recommends that
patients taking medium- or high-dose ICS delivered by metered-dose inhalers (MDIs) should
use a spacer device.
Methods: This randomized, open-label, 12-week, non-inferiority study compared the efficacy
and safety of ciclesonide 160 mg once daily delivered via hydrofluoroalkane-MDI alone (CIC160)
or with a spacer (either an AeroChamber Plus [CIC160P] or an AeroChamber MAX [CIC160M]) in
patients with persistent asthma. The primary efficacy variable was change in forced expiratory
volume in 1 s (FEV1) from baseline to study end.
Results: Significant improvements in FEV1 were observed from baseline to study end in each
treatment group; least squares mean change from baseline ranged between 0.32 and 0.34L
in the per-protocol (PP) analysis and similar results were observed for the intention-to-treat
(ITT) analysis (p< 0.0001 for all). Non-inferiority of CIC160P and CIC160M to CIC160 was
observed for both PP and ITT populations (p< 0.0001 [one-sided]). In all groups, daily asthma
symptom scores were reduced to 0 and significant reductions were observed in rescue medica-
tion use at study end (p< 0.0001 versus baseline for all). Ciclesonide was well tolerated in all
groups and no cases of oral candidiasis were reported. Morning serum cortisol levels signifi-
cantly increased in all groups from baseline to study end (p 0.0389), with no significant
between-treatment differences.
Conclusion: In patients with persistent asthma, ciclesonide was shown to have similar efficacy
and tolerability when administered via MDI alone or with a spacer.
ª 2009 Elsevier Ltd. All rights reserved.)7531 84 2268; fax: þ49 (0)7531 84 94732.
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1644 R. Engelsta¨tter et al.Introduction salbutamol 200e400 mg. If the latter was not demonstrated,Inhaled corticosteroids (ICS) are the recommended first-line
therapy for adults and children of all ages with persistent
asthma.1 ICS elicit a potent anti-inflammatory action,
resulting in decreases in bronchial hyperresponsiveness,
improvements in lung function, and reductions in asthma
symptoms and rescuemedication use.1e3 In addition, ICS are
generally well tolerated at therapeutic doses and have an
excellent riskebenefit ratio.1,3
Spacer devices developed for use with pressurized
metered-dose inhalers (MDIs) can be used to increase the
quantity of ICS deposited in the lung and, therefore,
potentially improve efficacy in patients who have problems
with inhalation coordination.4,5 Furthermore, as spacers
retain the large drug particles that might ordinarily be
deposited in the oropharynx, their use may result in lower
oropharyngeal deposition and oral bioavailability, thereby
reducing the occurrence of oropharyngeal AEs,4,5 and the
systemic bioavailability of some ICS.6,7 The Global Initiative
for Asthma (GINA) recommends that patients of all ages
taking medium- or high-dose ICS delivered by MDIs should
use a spacer device.1
Ciclesonide is a novel lung-activated ICS that has a small
particle size, low oral bioavailability and high pulmonary
deposition.8e10 One pharmacokinetic study showed that the
use of a spacer (AeroChamber Plusd; Trudell Medical
International, Ontario, Canada) did not change lung depo-
sition and systemic exposure;11 however, new regulatory
guidelines from the European Medicines Agency require
additional clinical data on the use of spacers.12,13 There-
fore, the aim of the current 12-week study was to compare
the efficacy and safety of ciclesonide MDI with or without
the use of a spacer. As the AeroChamber Plusd is recom-
mended in the product characteristics for ciclesonide in
most countries, this spacer was used in the current study,
as well as a newly available spacer, the AeroChamber MAXd
(Trudell Medical International, Ontario, Canada). This
spacer differs from the AeroChamber Plusd as it is manu-
factured from an anti-static polymer, which may help
improve aerosol suspension time and drug availability for
patients with lower tidal volumes, as well as for those who
have difficulty coordinating the actuation of pressurized
MDIs and inhaling correctly.Methods
Patients
Male and female patients aged 12e75 years with a
6-month history of persistent asthma (as defined by GINA
guidelines 2004)14 were eligible for inclusion in the study.
Both patients previously receiving rescue medication only
and patients treated with a controller drug during the past
4 weeks were enrolled. During run in, only rescue medica-
tion (salbutamol) was permitted. Patients were randomized
into the treatment period if they had an FEV1 61e90% of
predicted and FEV1 reversibility of 15% after inhalation ofd Trade marks and registered trade marks of Trudell Medical Internata 15% fluctuation in diurnal peak expiratory flow (PEF),
airway responsiveness or historical data were also
accepted.
Patients were excluded from the study if they had: other
relevant lung diseases, including chronic obstructive
pulmonary disease, a smoking history of 10 pack years (2
pipe years), a concomitant severe disease, or a disease that
contraindicated ICS use. Female patients were excluded if
they were pregnant, breast feeding or were not using
appropriate contraception. Patients who had used systemic
steroids 4 weeks prior to baseline, or >3 times during the
last 6 months before baseline were also excluded.
Study design
This was a randomized, open-label, parallel-group, multi-
national, multicenter, non-inferiority study, with three
treatment arms. The study consisted of a 1e3-week run-in
period and a 12-week treatment period, and was conducted
in 52 study centers worldwide (Canada, France, Germany,
Hungary, India and Italy). Patients visited their study centers
up to four times during the run-in period and at Weeks 0, 4, 8
and 12 during treatment.
Patients who fulfilled the inclusion criteria were
randomized into three groups to receive ciclesonide 160 mg
once daily in the evening (PM) via hydrofluoroalkane (HFA)e
MDI only (CIC160), via HFAeMDI and an AeroChamber Plusd
spacer (CIC160P) or via HFAeMDI and an AeroChamber MAXd
spacer (CIC160M). With the exception of study medication
and rescue medication, no other asthma drugs were
permitted during the treatment period.
Randomizationwas carried out in a stratifiedmanner using
the following factors: current smoking (yes/no), inhaled
corticosteroid pretreatment (yes/no), inhalation technique
without spacer (good/bad) and FEV1 value (high/low). Treat-
mentwasbalancedata ratioof1:1:1withineach stratum.The
randomization list was generated by the sponsor using a vali-
dated multiplicative congruential pseudo-random number
generator and transferred to the randomization service
provider. Investigators interacted with the randomization
service provider bymeans of an automated facsimile formand
the automated system allocated the patient randomly to one
of the three treatment groups via a return fax.
The protocol for this study was reviewed and approved by
the appropriate regional Institutional Review Boards or Inde-
pendent Ethics Committees, and the study was conducted in
accordance with the Declaration of Helsinki in its revised
versions of Tokyo (1975), Venice (1983) and Somerset West
(1996). The study followed the rules of the International
Conference on Harmonization and the Consolidated Good
Clinical Practice Guideline E6. Written, informed consent was
obtained from all patients before enrollment into the trial.
Efficacy measures
Pulmonary function
FEV1 and forced vital capacity (FVC) measurements were
taken between 6 and 10 am (1.5 h from the measurementsional.
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rest period and after rescue medication had been withheld
for 4 h. The highest of three technically acceptable read-
ings was noted in patient case-report forms, and all spiro-
grams were checked for acceptability and reproducibility in
accordance with American Thoracic Society guidelines.15
Home PEF readings were taken daily using a Mini-
Wright PEF meter (Clement Clarke International Limited,
Essex, UK). Measurements were taken in the morning
immediately after getting up. The highest of three recor-
ded values was used for evaluation.
Asthma control, rescue medication use and asthma
symptom scores
Asthma control was evaluated daily, and was defined as
a day with no asthma symptoms and no rescue medication
use. Salbutamol use was recorded in patient diaries
throughout the study period. Asthma symptom scores were
also recorded in patient diaries and rated twice daily on
a scale of 0e4 (0Z very well, no symptoms; 4Z asthma
very bad, unable to carry out daily activities).
Asthma exacerbations
Patients with asthma exacerbations requiring treatment
with oral corticosteroids were withdrawn from the study
and were treated accordingly.
Safety evaluation
Safety was assessed by recording the occurrence of adverse
events (AEs) during each study visit and in patient diaries.
Cases of suspected oral candidiasis were to be confirmed by
a swab test and positive culture. Vital sign measurements,
physical examination and routine laboratory investigations,
including hematology, biochemistry and urinalysis, were
also assessed at baseline and the end of the study. Blood
samples drawn at baseline and the end of the treatment
period were used to measure AM cortisol levels.
Statistical analysis
The primary efficacy variable was change in FEV1 (L) from
baseline to study end. Secondary efficacy variables
included change from baseline to study end in morning PEF,
FVC, asthma symptom score, rescue medication use,
number of patients with an asthma exacerbation and
asthma control. Variables evaluated for safety included
AEs, number of patients with local oropharyngeal AEs,
serum cortisol, vital signs (blood pressure and heart rate),
physical examination and compliance to study medication.
All lung function variables (FEV1, FVC and PEF absolute
values) were assessed using analysis of covariance
models.16,17 Non-parametric comparisons of asthma
symptom scores, rescue medication use and percentage of
days with asthma control were assessed with Pratt’s-
modified Wilcoxon’s signed-rank test for within-group
comparisons and the ManneWhitney U-test for between-
group comparisons. Pratt’s modified Wilcoxon’s signed-rank
test was also used to evaluate serum cortisol. The between-
treatment differences for this variable were adjusted for
country utilizing the non-parametric van Elteren test.18
For all variables, the between-treatment differences
from baseline until study end were determined in a pair-
wise manner. Two-sided 95% confidence intervals (CIs) wereprovided for both within- and between-treatment differ-
ences. For between-treatment differences, a one-sided
p-value was given for non-inferiority tests. The non-inferi-
ority acceptance limits were set to 200 mL for FEV1 and
FVC and 25 L/min for morning PEF. For asthma symptom
scores, the non-inferiority acceptance limit was þ0.30.
For efficacy variables, the intention-to-treat (ITT)
patient population was analyzed, and included all
randomized patients who had taken at least one dose of
study medication. Non-inferiority of CIC160P and CIC160M
to CIC160 was assessed using the per-protocol (PP) pop-
ulation. The PP population included all patients in the ITT
population who had no major protocol violations, and who
had participated in the study as intended. The safety
analysis included all randomized patients who had received
at least one dose of study medication.
To achieve a power of 90% for correctly concluding non-
inferiority at a one-sided significance level of 0.0125 for
CIC160P or CIC160M to CIC160, 127 patients per group
(nZ 381 total) were needed, assuming a mean difference
of 0 mL in FEV1 for CIC160P or CIC160M to CIC160 in the
presence of a standard deviation of 450 mL and a non-
inferiority acceptance limit of 200 mL. Assuming that
about 15% of patients would not be included in the PP
analysis, 150 patients were planned to be randomized per
group (450 randomized patients in total).
Results
Patients
Of the 498 patients enrolled, 469 were randomized to
treatment (CIC160, nZ 150; CIC160P, nZ 162; CIC160 M,
nZ 157). One randomized patient in the CIC160 group
failed to take at least one dose of study medication and
was, therefore, excluded from analysis; leaving a total of
468 randomized patients. A total of 21 patients (CIC160,
nZ 5; CIC160P, nZ 7; CIC160M, nZ 9) withdrew early
from the study. The main reason for study discontinuation
was the occurrence of AEs (CIC160, nZ 2; CIC160P, nZ 2;
CIC160M, nZ 4). The PP population consisted of 423
patients (CIC160, nZ 135; CIC160P, nZ 144; CIC160M,
nZ 144).
The demographic and baseline characteristic data were
similar between treatment groups (Table 1). Median
compliance to study medication during the treatment
period, recorded by daily diary entries, was 100% in all
three treatment groups in the PP analysis (range: CIC160,
86e103%; CIC160P, 92e104%; CIC160M, 90e100%).
Efficacy measures
Pulmonary function
Significant improvements in FEV1 from baseline to study
end were noted in each treatment group (least squares [LS]
mean change from baseline ranged between 0.32 and 0.34 L
for the PP analysis and between 0.33 and 0.34 L for the ITT
analysis; p< 0.0001 for all; Table 2; Fig. 1). Non-inferiority
of CIC160P and CIC160M to CIC160 was shown in both the PP
and ITT populations (p< 0.0001 [one-sided]; Table 2). For
the PP analysis, the LS mean for the treatment difference
Table 1 Patient demographic and baseline characteristics.













Median age, years 38 39 43 37 38 42
Gender, n (%)
Male 81 (54.4) 70 (43.2) 66 (42.0) 75 (55.6) 62 (43.1) 62 (43.1)
Female 68 (45.6) 92 (56.8) 91 (58.0) 60 (44.4) 82 (56.9) 82 (56.9)
Race, n (%)
Asian 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Black 1 (0.7) 1 (0.6) 0 (0.0) 1 (0.7) 1 (0.7) 0 (0.0)
Caucasian 147 (98.7) 159 (98.1) 157 (100.0) 134 (99.3) 143 (99.3) 144 (100.0)
Other 0 (0.0) 2 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Smoking status, n (%)
Non/ex-smokers 143 (96.0) 153 (94.4) 149 (94.9) 129 (95.6) 135 (93.8) 136 (94.4)
Current smokers 6 (4.0) 9 (5.6) 8 (5.1) 6 (4.4) 9 (6.3) 8 (5.6)
Mean FEV1 (SD), [L] 2.4 0.6 2.3 0.6 2.3 0.6 2.4 0.6 2.4 0.6 2.3 0.6
Mean FEV1,
% predicted ( SD)
75.9 7.7 75.0 7.0 76.5 7.5 75.6 7.5 75.5 6.9 76.1 7.1
Mean FEV1
reversibility (SD)
23.4 9.3 23.0 7.6 22.8 8.7 23.8 9.3 22.8 7.2 22.3 7.1
ITTZ intention to treat; PPZ per protocol; CIC160Z ciclesonide 160 mg; CIC160PZ ciclesonide 160 mg administered by AeroChamber
Plusd spacer; CIC160MZ ciclesonide 160 mg administered by AeroChamber Maxd spacer; FEV1Z forced expiratory volume in 1 s; and
SDZ standard deviation.
1646 R. Engelsta¨tter et al.was 0.020L (95% CI: e0.073, 0.112) for CIC160P versus
CIC160, and 0.018 L (95% CI: e0.075, 0.111) for CIC 160M
versus CIC160.
For FVC, significant within-treatment increases in all
three treatment groups were observed from baseline to
study end (p< 0.0001 for all, PP and ITT analyses). Non-
inferiority of CIC160P (95% CI: e0.100, 0.117) and CIC160M
(95% CI: e0.112, 0.106) to CIC160 was shown for FVC in
the PP analysis (p 0.0002 [one-sided]; Table 2). Similar
findings were obtained for the ITT analysis.
Home morning PEF values increased during the study in
all treatment groups, with statistically significant within-
group improvements observed for CIC160 (p 0.0026, ITT
and PP analyses) and CIC160P patients (p 0.0025, ITT and
PP analyses; Table 2). In the PP analysis for morning PEF,
CIC160P (95% CI: 11.2, 10.1) and CIC160M (95% CI: 23.9,
2.5) were non-inferior to CIC160 (p 0.0156 [one-sided];
Table 2). This was supported by findings in the ITT analysis.
Asthma symptom scores and rescue medication use
In the PP analysis, median daily asthma symptom scores
were reduced to 0 in all treatment groups at the end of the
treatment period (p< 0.0001 for all versus baseline; Table
2). Exploratory non-inferiority of CIC160P and CIC160M to
CIC160 was shown (95% CI: 0.26, 0.12 for CIC160P; 0.00,
0.29 for CIC160M). Non-inferiority was also shown in the ITT
analysis.
Significant reductions in rescue medication use were
observed in each treatment group from baseline to study
end (p< 0.0001 for all; Table 2); the median rescue medi-
cation use decreased to 0.00 puffs/day at the end of the
treatment period in all groups. No between-treatment
group differences were observed (Table 2).Asthma exacerbations
No asthma exacerbations were reported in the CIC160
group. Two patients in the CIC160P group and three
patients in the CIC160M group experienced asthma
exacerbations.
Days with asthma control
Significant increases were observed during the study in all
groups for the median percentage of days with asthma
control (all p< 0.0001; Fig. 2). No statistically significant
between-treatment differences were observed in asthma
control.
Safety
Ciclesonide was well tolerated in all treatment groups. A
total of 104 patients (CIC160, nZ 29 [19.5%]; CIC160P,
nZ 34 [21.0%]; CIC160M, nZ 41 [26.1%]) reported 145 AEs
(CIC160, nZ 41; CIC160P, nZ 51; CIC160M, nZ 53)
throughout the study period. Frequently reported AEs
were: nasopharyngitis (CIC160, nZ 3 [2.0%]; CIC160P,
nZ 6 [3.7%]; CIC160M, nZ 6 [3.8%]); asthma (CIC160,
nZ 4 [2.7%]; CIC160P, nZ 6 [3.7%]; CIC160M, nZ 4
[2.5%]); upper respiratory tract infection (CIC160, nZ 3
[2.0%]; CIC160P, nZ 1 [0.6%]; CIC160M, nZ 4 [2.5%]);
bronchitis (CIC160, nZ 3 [2.0%]; CIC160P, nZ 1 [0.6%];
CIC160M, nZ 3 [1.9%]); acute bronchitis (CIC160, nZ 4
[2.7%]; CIC160P, nZ 1 [0.6%]; CIC160M, nZ 1 [0.6%]); and
rhinitis (CIC160, nZ 0 [0.0%]; CIC160P, nZ 0 [0.0%];
CIC160M, nZ 4 [2.5%]). The majority of AEs were mild or
moderate in intensity.
In those patients who experienced AEs, over 96% of
patients had AEs that were judged by investigators and the
study sponsor as being not related or unlikely related to
Table 2 Within- and between-treatment differences for primary and secondary variables (per-protocol and intention-to-treat
analyses).
Variable ITT population PP population
CIC160 CIC160P CIC160M CIC160 CIC160P CIC160M
FEV1 (L)
n 149 160 157 130 139 136
LS mean at baseline 2.36 2.36 2.36 2.37 2.37 2.37
LS mean change from baseline (SE) 0.33 0.07 0.34 0.07 0.34 0.07 0.32 0.07 0.34 0.07 0.34 0.07
p-Value versus baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
One-sided p-value for non-inferiority N/A <0.0001 <0.0001 N/A <0.0001 <0.0001
FVC (L)
n 149 160 157 130 139 136
LS mean at baseline 3.14 3.14 3.14 3.15 3.15 3.15
LS mean change from baseline ( SE) 0.37 0.08 0.37 0.08 0.37 0.08 0.36 0.09 0.37 0.08 0.36 0.08
p-Value versus baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
One-sided p-value for non-inferiority N/A 0.0001 0.0001 N/A 0.0001 0.0002
Morning PEF (L/min)
n 147 160 153 129 139 139
LS mean at baseline 354 354 354 352 352 352
LS mean change from baseline 26 8 23 8 12 8 25 8 25 8 12 8
p-Value versus baseline 0.0012 0.0025 0.1239 0.0026 0.0022 0.1353
One-sided p-value for non-inferiority N/A <0.0001 0.0164 N/A <0.0001 0.0156
Asthma symptom sum score
n 140 150 143 116 128 129
Median score at baseline 0.66 0.91 0.79 0.71 0.82 0.76
Median score at study end 0.00 0.00 0.14 0.00 0.00 0.00
p-Value versus baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Rescue medication
use [puffs/day]
n 147 160 153 128 139 138
Median score at baseline 0.71 1.00 0.71 0.79 1.00 0.71
Median score at study end 0.00 0.00 0.00 0.00 0.00 0.00
p-Value versus baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
p-Value versus CIC160 N/A 0.0718 0.5825 N/A 0.0940 0.2705
ITTZ intention to treat; PPZ per protocol; CIC160Z ciclesonide 160 mg, CIC160MZ ciclesonide 160 mg administered by AeroChamber
Maxd spacer; CIC160PZ ciclesonide 160 mg administered by AeroChamber Plusd spacer; FEV1Zforced expiratory volume in 1 s;
LSZ least squares; SEZ standard error; FVCZ forced vital capacity; and PEFZ peak expiratory flow.
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CIC160, nZ 2 (hypertensive crisis, osteotomy); CIC160P,
nZ 4 (two occurrences of cholangitis, pancreatic carci-
noma, pancreatitis chronic); and CIC160M, nZ 1 (abortion
spontaneous), although none were considered to be related
to study medication. There were no cases of oral candidi-
asis throughout the study.
Morning serum cortisol levels significantly increased in
all groups from baseline to study end (p 0.0389; safety
population; Table 3). No significant between-treatment
differences in serum cortisol levels were observed. No
clinically relevant changes in laboratory values, vital sign
assessments or physical examinations were observed in any
treatment group over the course of the study.
Discussion
In patients with persistent asthma, ciclesonide was
demonstrated to have similar efficacy when administeredvia MDI alone or with a spacer. In addition, there was no
difference in the safety of ciclesonide when administered
with or without a spacer.
In all treatment groups, ciclesonide demonstrated
significant improvements from baseline to study end in
pulmonary function (FEV1, FVC and AM PEF), asthma
symptom scores, rescue medication use and percentage of
days with asthma control. Non-inferiority of ciclesonide
when administered via a spacer compared with adminis-
tration without a spacer was shown for the primary efficacy
variable (change in FEV1 from baseline to study end), as
well as for the secondary variables FVC, AM PEF and asthma
symptom scores. No significant differences between treat-
ments were noted for the changes in rescue medication use
and percent days with asthma control.
Although guidelines recommend that patients of all ages
taking medium- or high-dose ICS delivered by MDIs should
use a spacer device,1 the use of spacers has been largely
based on data with older chlorofluorocarbon (CFC)-MDIs.
Figure 1 Change in forced expiratory volume in 1 s over the
study period in the intention-to-treat population. FEV1Z
forced expiratory volume in 1 s; CIC160Z ciclesonide 160 mg;
CIC160PZ ciclesonide 160 mg administered by AeroChamber
Plusd spacer; CIC160MZ ciclesonide 160 mg administered by
AeroChamber Maxd spacer.
Figure 2 Percentage of days with asthma control before and
after treatment) in the intention-to-treat (A) and per-protocol
(B) populations. )Percentage over the last 14 days before the
randomization visit and the last 28 days before the last visit.
CIC160Z ciclesonide 160 mg; CIC160PZ ciclesonide 160 mg
administered by AeroChamber Plusd spacer; CIC160MZ cicle-
sonide 160 mg administered by AeroChamber Maxd spacer.
Within-treatment comparisons: p< 0.0001 for all groups.
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lung deposition, and may reduce local and systemic side
effects. However, for some ICS, the HFA formulations
replacing the old phased-out CFC inhaler devices provide an
aerosol of smaller particle size, resulting in less oral depo-
sition and greater lung deposition.19 This may result in
a reduction in oral side effects and greater local efficacy at
equivalent ex-actuator doses, but also greater systemic
exposure and risk of systemic side effects.19 Therefore, for
HFA-MDIs, the focus of concern may switch and the use of
a spacer may depend on the properties of the individual ICS.
The current findings suggest that the addition of a spacer
to the ciclesonide HFAeMDI device did not further increase
the efficacy of ciclesonide in an average patient with
persistent asthma. This is also supported by other studies
where ciclesonide administered without a spacer signifi-
cantly improved asthma control in large patient pop-
ulations.20e24 However, patients having problems with
inhalation coordination may still benefit from spacer use.5
It should be noted that to avoid bias in the current study,
none of the participants were selected based on their
inhalation technique. In addition, because of the use of the
spacers in the current study, blinding was not possible and
the study had an open design. However, in order to improve
the quality of the study, an automated randomization
procedure was used so that the investigators were guided
in the randomization of the patients, preventing any
subjective choices.
Over the 12-week study, safety data revealed no
safety issues when ciclesonide was administered either
with or without a spacer. Ciclesonide use did not result in
any cases of oral candidiasis during the current study in
any treatment group. These findings support those of
previous studies that have demonstrated that ciclesonide
is associated with minimal local AEs.23e25 No clinicallyrelevant effects on laboratory, physical or vital sign
measurements were observed in any of the treatment
groups. Furthermore, ciclesonide had no suppressive
effects on morning serum cortisol levels in the current
study. Although morning cortisol levels provide only very
limited information on any HPA-axis suppressive effects,
the relatively low dose of ciclesonide administered in this
study, as well as previously reported data that found no
suppressive effect at higher doses of ciclesonide, make it
extremely unlikely that 24-h serum profiles or other
markers of HPA-axis function would have revealed
a different outcome.
In conclusion, ciclesonide is effective and well tolerated
in patients with asthma when administered with or without
the addition of a spacer. In addition, the AeroChamber
MAXd had no apparent benefits over the AeroChamber
Plus.d
Table 3 Change in median morning serum cortisol.
Serum cortisol (mmol/L) Safety population
CIC160 (NZ 114) CIC160P (NZ 118) CIC160M (NZ 109)
Baseline 0.30 0.32 0.32
Study end 0.36 0.37 0.34
HL point estimate 0.04 0.04 0.02
95% confidence interval 0.02, 0.06 0.02, 0.06 0.00, 0.04
p-Value versus baseline 0.0001 0.0001 0.0389
p-Value versus CIC160 N/A 0.6656 0.1768
CIC160Z ciclesonide 160 mg; CIC160 MZ ciclesonide 160 mg administered by AeroChamber Maxd spacer; CIC160PZ ciclesonide 160 mg
administered by AeroChamber Plusd spacer; and HLZHodges-Lehmann.
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